Multimedialna platforma wiedzy medycznej Internetowa Księgarnia Medyczna Kalendarium Konferencji
Rheumatology Forum
MENU
Shortcuts Submit an article Author Guidelines Ahead Of Print Editorial Team

open access

Vol 4, No 3 (2018)
Review paper
Published online: 2018-10-26
View PDF (Polish) Download PDF file
Get Citation

Serological markers in the diagnosis of rheumatoid arthritis — a clinician’s perspective

Cezary Iwaszkiewicz1, Piotr Leszczyński2
DOI: 10.5603/FR.2018.0005
·
Forum Reumatol 2018;4(3):169-177.
Affiliations
  1. Oddział Reumatologii i Osteoporozy, Szpital im. Józefa Strusia w Poznaniu
  2. Oddział Reumatologii i Osteoporozy, Szpital im. Józefa Strusia w Poznaniu oraz Pracownia Chorób Metabolicznych Kości i Tkanki Łącznej, Katedra Reumatologii i Rehabilitacji, Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu

open access

Vol 4, No 3 (2018)
Review
Published online: 2018-10-26

Abstract

The paper summarises the present knowledge of the role of autoantibodies in the diagnosis of rheumatoid arthritis. The starting point were the current rheumatoid arthritis classification criteria. The first part presents the diagnostic features of rheumatoid factor and anti-citrullinated protein/peptide antibodies, while the second part provides the answers to the essential clinical questions related to their use. This article, as opposed to more comprehensive papers in the field of immunology, focuses on daily rheumatological practice.

Forum Reumatol. 2018, tom 4, nr 3: 169–177

Abstract

The paper summarises the present knowledge of the role of autoantibodies in the diagnosis of rheumatoid arthritis. The starting point were the current rheumatoid arthritis classification criteria. The first part presents the diagnostic features of rheumatoid factor and anti-citrullinated protein/peptide antibodies, while the second part provides the answers to the essential clinical questions related to their use. This article, as opposed to more comprehensive papers in the field of immunology, focuses on daily rheumatological practice.

Forum Reumatol. 2018, tom 4, nr 3: 169–177

Full Text:

View PDF (Polish) Download PDF file
Get Citation

Keywords

rheumatoid arthritis; anti-citrullinated protein antibodies; ACPA; anti-cyclic citrullinated peptide antibodies; anti-CCP; aCCP; rheumatoid factor; RF

About this article
Title

Serological markers in the diagnosis of rheumatoid arthritis — a clinician’s perspective

Journal

Rheumatology Forum

Issue

Vol 4, No 3 (2018)

Article type

Review paper

Pages

169-177

Published online

2018-10-26

Page views

1328

Article views/downloads

1090

DOI

10.5603/FR.2018.0005

Bibliographic record

Forum Reumatol 2018;4(3):169-177.

Keywords

rheumatoid arthritis
anti-citrullinated protein antibodies
ACPA
anti-cyclic citrullinated peptide antibodies
anti-CCP
aCCP
rheumatoid factor
RF

Authors

Cezary Iwaszkiewicz
Piotr Leszczyński

References (64)
  1. Kourilovitch M, Galarza-Maldonado C, Ortiz-Prado E. Diagnosis and classification of rheumatoid arthritis. J Autoimmun. 2014; 48-49: 26–30.
    CrossRefPubMed
  2. Smolen JS, Landewe R, Bijlsma J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017; 76(6): 960–977.
  3. Castro C, Gourley M. Diagnostic testing and interpretation of tests for autoimmunity. J Allergy Clin Immunol. 2010; 125(2 Suppl 2): S238–S247.
    CrossRefPubMed
  4. Bonaguri C, Melegari A, Ballabio A, et al. Italian multicentre study for application of a diagnostic algorithm in autoantibody testing for autoimmune rheumatic disease: conclusive results. Autoimmun Rev. 2011; 11(1): 1–5.
    CrossRefPubMed
  5. Newkirk MM. Rheumatoid factors: what do they tell us? J Rheumatol. 2002; 29(10): 2034–2040.
    PubMed
  6. Nowak U, Gill K, Skamene E, et al. Rheumatoid factor induction in murine models of liver injury. Clin Exp Immunol. 2007; 147(2): 324–329.
    CrossRefPubMed
  7. Aletaha D, Neogi T, Silman AJ, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2010; 69(9): 1580–1588.
    CrossRefPubMed
  8. Deane KD. Preclinical rheumatoid arthritis (autoantibodies): an updated review. Curr Rheumatol Rep. 2014; 16(5): 419.
    CrossRefPubMed
  9. Karimifar M, Moussavi H, Babaei M, et al. The association of immunoglobulin A, immunoglobulin G and anti-cyclic citrullinated peptide antibodies with disease activity in seronegative rheumatoid arthritis patients. J Res Med Sci. 2014; 19(9): 823–826.
    PubMed
  10. Rantapää-Dahlqvist S, de Jong BAW, Berglin E, et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum. 2003; 48(10): 2741–2749.
    CrossRefPubMed
  11. Nielen MMJ, van Schaardenburg D, Reesink HW, et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum. 2004; 50(2): 380–386.
    CrossRefPubMed
  12. Majka DS, Deane KD, Parrish LA, et al. Duration of preclinical rheumatoid arthritis-related autoantibody positivity increases in subjects with older age at time of disease diagnosis. Ann Rheum Dis. 2008; 67(6): 801–807.
    CrossRefPubMed
  13. Kolfenbach JR, Deane KD, Derber LA, et al. Autoimmunity to peptidyl arginine deiminase type 4 precedes clinical onset of rheumatoid arthritis. Arthritis Rheum. 2010; 62(9): 2633–2639.
    CrossRefPubMed
  14. Nell-Duxneuner V, Machold K, Stamm T, et al. Autoantibody profiling in patients with very early rheumatoid arthritis: a follow-up study. Ann Rheum Dis. 2010; 69(1): 169–174.
    CrossRefPubMed
  15. Carpenter L, Norton S, Nikiphorou E, et al. Early Rheumatoid Arthritis Study and the Early Rheumatoid Arthritis Network. Reductions in Radiographic Progression in Early Rheumatoid Arthritis Over Twenty-Five Years: Changing Contribution From Rheumatoid Factor in Two Multicenter UK Inception Cohorts. Arthritis Care Res (Hoboken). 2017; 69(12): 1809–1817.
    CrossRefPubMed
  16. Nishimura K, Sugiyama D, Kogata Y, et al. Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med. 2007; 146(11): 797–808.
    PubMed
  17. Watanabe S, Gono T, Nishina K, et al. Rheumatoid factor is correlated with disease activity and inflammatory markers in antineutrophil cytoplasmic antibody-associated vasculitis. BMC Immunol. 2017; 18(1): 53.
    CrossRefPubMed
  18. Punzi L, Podswiadek M, Oliviero F, et al. Laboratory findings in psoriatic arthritis. Reumatismo. 2007; 59 Suppl 1: 52–55.
    PubMed
  19. Elkayam O, Segal R, Lidgi M, et al. Positive anti-cyclic citrullinated proteins and rheumatoid factor during active lung tuberculosis. Ann Rheum Dis. 2006; 65(8): 1110–1112.
    CrossRefPubMed
  20. Schattner A, Shani A, Talpaz M, et al. Rheumatoid factors in the sera of patient with gastrointestinal carcinoma. Cancer. 1983; 52(11): 2156–2161.
    PubMed
  21. Ingegnoli F, Castelli R, Gualtierotti R. Rheumatoid factors: clinical applications. Dis Markers. 2013; 35(6): 727–734.
    CrossRefPubMed
  22. Zengin O, Yıldız H, Demir ZH, et al. Rheumatoid factor and anti-cyclic citrullinated peptide (anti-CCP) antibodies with hepatitis B and hepatitis C infection: Review. Adv Clin Exp Med. 2017; 26(6): 987–990.
    PubMed
  23. Puszczewicz M, Iwaszkiewicz C. Role of anti-citrullinated protein antibodies in diagnosis and prognosis of rheumatoid arthritis. Arch Med Sci. 2011; 7(2): 189–194.
    CrossRefPubMed
  24. Ludwig RJ, Vanhoorelbeke K, Leypoldt F, et al. Mechanisms of Autoantibody-Induced Pathology. Front Immunol. 2017; 8: 603.
    CrossRefPubMed
  25. Infantino M, Manfredi M, Meacci F, et al. Anti-citrullinated peptide antibodies and rheumatoid factor isotypes in the diagnosis of rheumatoid arthritis: an assessment of combined tests. Clin Chim Acta. 2014; 436: 237–242.
    CrossRefPubMed
  26. Ioan-Facsinay A, el-Bannoudi H, Scherer HU, et al. Anti-cyclic citrullinated peptide antibodies are a collection of anti-citrullinated protein antibodies and contain overlapping and non-overlapping reactivities. Ann Rheum Dis. 2011; 70(1): 188–193.
    CrossRefPubMed
  27. Goules JD, Goules AV, Tzioufas AG. Fine specificity of anti-citrullinated peptide antibodies discloses a heterogeneous antibody population in rheumatoid arthritis. Clin Exp Immunol. 2013; 174(1): 10–17.
    CrossRefPubMed
  28. Ioan-Facsinay A, Willemze A, Robinson DB, et al. Marked differences in fine specificity and isotype usage of the anti-citrullinated protein antibody in health and disease. Arthritis Rheum. 2008; 58(10): 3000–3008.
    CrossRefPubMed
  29. van der Woude D, Rantapää-Dahlqvist S, Ioan-Facsinay A, et al. Epitope spreading of the anti-citrullinated protein antibody response occurs before disease onset and is associated with the disease course of early arthritis. Ann Rheum Dis. 2010; 69(8): 1554–1561.
    CrossRefPubMed
  30. Brink M, Hansson M, Mathsson L, et al. Multiplex analyses of antibodies against citrullinated peptides in individuals prior to development of rheumatoid arthritis. Arthritis Rheum. 2013; 65(4): 899–910.
    CrossRefPubMed
  31. Ménard HA. Anti-cyclic citrullinated peptide in preclinical rheumatoid arthritis. Food for thought. J Rheumatol. 2009; 36(4): 663–664.
    CrossRefPubMed
  32. van Beers JJ, Willemze A, Jansen JJ, et al. ACPA fine-specificity profiles in early rheumatoid arthritis patients do not correlate with clinical features at baseline or with disease progression. Arthritis Res Ther. 2013; 15(5): R140.
    CrossRefPubMed
  33. Willemze A, Böhringer S, Knevel R, et al. The ACPA recognition profile and subgrouping of ACPA-positive RA patients. Ann Rheum Dis. 2012; 71(2): 268–274.
    CrossRefPubMed
  34. van Venrooij WJ, van Beers JJ, Pruijn GJM. Anti-CCP Antibody, a Marker for the Early Detection of Rheumatoid Arthritis. Ann N Y Acad Sci. 2008; 1143: 268–285.
    CrossRefPubMed
  35. van Venrooij WJ, van Beers JJ, Pruijn GJM. Anti-CCP antibodies: the past, the present and the future. Nat Rev Rheumatol. 2011; 7(7): 391–398.
    CrossRefPubMed
  36. Payet J, Goulvestre C, Bialé L, et al. Anticyclic citrullinated peptide antibodies in rheumatoid and nonrheumatoid rheumatic disorders: experience with 1162 patients. J Rheumatol. 2014; 41(12): 2395–2402.
    CrossRefPubMed
  37. Vander Cruyssen B, Hoffman IEA, Zmierczak H, et al. Anti-citrullinated peptide antibodies may occur in patients with psoriatic arthritis. Ann Rheum Dis. 2005; 64(8): 1145–1149.
    CrossRefPubMed
  38. Bogliolo L, Alpini C, Caporali R, et al. Antibodies to cyclic citrullinated peptides in psoriatic arthritis. J Rheumatol. 2005; 32(3): 511–515.
    PubMed
  39. Atzeni F, Sarzi-Puttini P, Lama N, et al. Anti-cyclic citrullinated peptide antibodies in primary Sjögren syndrome may be associated with non-erosive synovitis. Arthritis Res Ther. 2008; 10(3): R51.
    CrossRefPubMed
  40. Payet J, Belkhir R, Gottenberg JE, et al. ACPA-positive primary Sjögren's syndrome: true primary or rheumatoid arthritis-associated Sjögren's syndrome? RMD Open. 2015; 1(1): e000066.
    CrossRefPubMed
  41. Wang Y, Pei F, Wang X, et al. Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody for juvenile idiopathic arthritis. J Immunol Res. 2015; 2015: 915276.
    CrossRefPubMed
  42. Lipinska J, Smolewska E, Brozik H, et al. Anti-CCP antibodies in children with juvenile idiopathic arthritis (JIA) - diagnostic and clinical significance. Centr. Eur. J. Immunol. . 2008; 33(1): 19–23.
  43. Popescu C, Zofotă S, Bojincă V, et al. The significance of rheumatoid factor and anti-cyclic citrullinated peptide antibodies in systemic lupus erythematosus. Rom J Intern Med. 2013; 51(3-4): 179–187.
    PubMed
  44. Kim JO, Lee JS, Choi JY, et al. The relationship between peripheral arthritis and anti-cyclic citrullinated peptide antibodies in ankylosing spondylitis. Joint Bone Spine. 2013; 80(4): 399–401.
    CrossRefPubMed
  45. Labrador-Horrillo M, Martinez MaA, Selva-O'Callaghan A, et al. Anti-cyclic citrullinated peptide and anti-keratin antibodies in patients with idiopathic inflammatory myopathy. Rheumatology (Oxford). 2009; 48(6): 676–679.
    CrossRefPubMed
  46. Gokhan A, Turkeyler IH, Babacan T, et al. The antibodies cyclic citrullinated peptides (anti-CCP) positivity could be a promising marker in brucellosis patients presented with peripheric arthritis. Mod Rheumatol. 2014; 24(1): 182–187.
    CrossRefPubMed
  47. Uyanik A, Albayrak F, Uyanik MH, et al. Antibodies directed to cyclic citrullinated peptides in familial Mediterranean fever. Rheumatol Int. 2010; 30(4): 467–471.
    CrossRefPubMed
  48. Koga T, Migita K, Miyashita T, et al. Determination of anti-cyclic citrullinated peptide antibodies in the sera of patients with liver diseases. Clin Exp Rheumatol. 2008; 26(1): 121–124.
    PubMed
  49. Santiago M, Baron M, Miyachi K, et al. A comparison of the frequency of antibodies to cyclic citrullinated peptides using a third generation anti-CCP assay (CCP3) in systemic sclerosis, primary biliary cirrhosis and rheumatoid arthritis. Clin Rheumatol. 2008; 27(1): 77–83.
    CrossRefPubMed
  50. Fusconi M, Vannini A, Dall'Aglio AC, et al. Anti-cyclic citrullinated peptide antibodies in type 1 autoimmune hepatitis. Aliment Pharmacol Ther. 2005; 22(10): 951–955.
    CrossRefPubMed
  51. Dalkılıç E, Öksüz MF, Tufan AN, et al. Anti-cyclic citrullinated peptide and rheumatoid factor in patients with chronic hepatitis B and hepatitis B carriers. Eur J Rheumatol. 2015; 2(2): 62–65.
    CrossRefPubMed
  52. Cunha BM, Mota LM, Pileggi GS, et al. HIV/AIDS and rheumatoid arthritis. Autoimmun Rev. 2015; 14(5): 396–400.
    CrossRefPubMed
  53. Kakumanu P, Yamagata H, Sobel ES, et al. Patients with pulmonary tuberculosis are frequently positive for anti-cyclic citrullinated peptide antibodies, but their sera also react with unmodified arginine-containing peptide. Arthritis Rheum. 2008; 58(6): 1576–1581.
    CrossRefPubMed
  54. Laustriat G, Ruyssen-Witrand A, Constantin A, et al. Anti-citrullinated peptides antibodies in systemic sclerosis: Meta-analysis of frequency and meaning. Joint Bone Spine. 2018; 85(2): 147–153.
    CrossRefPubMed
  55. Iwaszkiewicz C, Puszczewicz M, Białkowska-Puszczewicz G. Diagnostic value of the anti-Sa antibody compared with the anti-cyclic citrullinated peptide antibody in rheumatoid arthritis. Int. J. Rheum. Dis. . 2015; 18(1): 46–51.
  56. Dogan M, Kucuksarac S, Tufekci O. Comparison of the diagnostic values in rheumatoid arthritis: anti-CCP antibodies and other serological tests. Biomedical Research. 2014; 25(3): 381–386.
  57. National Institute for Health and Care Excellence. Draft for consultation: rheumatoid arthritis in adults: management. 2018. www.nice.org.uk/guidance/GID-NG10014/documents/draft-guideline..
  58. Barra L, Pope J, Bessette L, et al. Lack of seroconversion of rheumatoid factor and anti-cyclic citrullinated peptide in patients with early inflammatory arthritis: a systematic literature review. Rheumatology (Oxford). 2011; 50(2): 311–316.
    CrossRefPubMed
  59. Burr ML, Viatte S, Bukhari M, et al. Long-term stability of anti-cyclic citrullinated peptide antibody status in patients with early inflammatory polyarthritis. Arthritis Res Ther. 2012; 14(3): R109.
    CrossRefPubMed
  60. Vos I, Van Mol C, Trouw LA, et al. Anti-citrullinated protein antibodies in the diagnosis of rheumatoid arthritis (RA): diagnostic performance of automated anti-CCP-2 and anti-CCP-3 antibodies assays. Clin Rheumatol. 2017; 36(7): 1487–1492.
    CrossRefPubMed
  61. Song JY, Li MX, Li S, et al. Diagnostic value of third generation anti-cyclic citrullinated peptide assay in rheumatoid factor negative rheumatoid arthritis. Int. J. Clin. Exp. Pathol. 2016; 9(10): 10728–10733.
  62. Pruijn GJm, Wiik A, van Venrooij WJ. The use of citrullinated peptides and proteins for the diagnosis of rheumatoid arthritis. Arthritis Res Ther. 2010; 12(1): 203.
    CrossRefPubMed
  63. Li Y, Zhang R, Han Y, et al. Proficiency testing for the detection of anti-citrullinated protein antibody in China. Clin Chim Acta. 2015; 450: 67–71.
    CrossRefPubMed
  64. Singh Sangha M, Wright ML, Ciurtin C. Strongly positive anti-CCP antibodies in patients with sacroiliitis or reactive arthritis post-E. coli infection: A mini case-series based review. Int J Rheum Dis. 2018; 21(1): 315–321.
    CrossRefPubMed

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Group sp. z o.o., Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl